Cancer scientists at Stanford and the Children’s Hospital of Philadelphia (CHOP) identified a protein, FOXO1, that improves the survival and function of CAR-T cells, which may lead to more effective CAR-T cell therapies and could potentially expand...
Artificial intelligence algorithms powered by deep learning improve skin cancer diagnostic accuracy for doctors, nurse practitioners and medical students in a study led by the Stanford Center for Digital Health.
Soft tissue sarcomas are rare and difficult to treat. Machine-learning tools designed at Stanford Medicine uncover distinct cellular communities that correlate with prognosis, immunotherapy success.
In honor of the 2024 World Cancer Day theme, “Close the Care Gap,” we highlight a few Stanford cancer researchers working to close the care gap in diverse populations through screening, clinical trials, prevention, and community engagement.
The Stanford Cancer Institute Early Drug Development (EDD) program brings in early-phase clinical trials so cancer patients can have access to innovative treatments that could provide a therapeutic benefit.
A molecular “snapshot” of a protein can be critical to understanding its function. Scientists at Stanford and NYU have published and investigated a new structure of the protein LAG-3 which could enable the development of new cancer treatments.
The new study found that an RNA-targeting CRISPR platform could tune immune cell metabolism without permanent genetic changes, potentially unveiling a relatively low-risk way to upgrade existing cell therapies for cancer.
The Office of Communication & Public Affairs is dedicated to sharing School of Medicine news with the media and helping journalists secure expert interviews, photographs and rich media for stories on medicine and health care.
